Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 10/20 | 0.75 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | DRD2 | P14416 | 1/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.43 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6613919 | 0.88 | SLC6A4 (0.78) | SLC6A4ALDH1A1DRD2SLC6A2SLC6A3 | |
| SCHEMBL6615645 | 0.86 | SLC6A4 (1.00) | SLC6A4DRD2SLC6A2SLC6A3CYP2A6 | |
| SCHEMBL6616255 | 0.78 | SLC6A4 (0.63) | SLC6A4ALDH1A1DRD2SLC6A2SLC6A3 | |
| SCHEMBL6613400 | 0.77 | SLC6A4 (0.66) | SLC6A4DRD2SLC6A2SLC6A3CYP2A6 | |
| SCHEMBL9381666 | 0.76 | SLC6A4 (0.64) | SLC6A4ALDH1A1DRD2SLC6A2SLC6A3 | |
| SCHEMBL9381661 | 0.76 | SLC6A4 (0.64) | SLC6A4ALDH1A1DRD2SLC6A2SLC6A3 | |
| SCHEMBL6616259 | 0.73 | SLC6A4 (0.60) | SLC6A4ALDH1A1DRD2SLC6A2CYP2A6 | |
| SCHEMBL6615099 | 0.72 | SLC6A4 (0.59) | SLC6A4ALDH1A1DRD2CYP2A6SMN1; SMN2 | |
| SCHEMBL1289737 | 0.71 | SLC6A4 (0.67) | SLC6A4 | |
| SCHEMBL6615485 | 0.66 | SLC6A4 (0.51) | SLC6A4ALDH1A1DRD2CYP2A6SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6822100-B2 | REACTING N-SULFONYL-3-VINYLINDOLE WITH RUTHENIUM COMPLEX IN PRESENCE OF ETHYL DIAZOACETATE AND TOLUENE; PSYCHOLOGICAL, SEXUAL, AND EATING DISORDERS | BRISTOL-MYERS SQUIBB COMPANY | 2004-11-23 | — | — | US | disclosed |
| US-6777437-B2 | ANTIDEPRESSANTS, ANXIOLYTIC AGENTS. SEXUAL DISORDERS | BRISTOL-MYERS SQUIBB COMPANY | 2004-08-17 | — | — | US | disclosed |
| US-20040143003-A1 | Cyclopropylindole derivatives as selective serotonin reuptake inhibitors | MATTSON RONALD J (US) | 2004-07-22 | — | — | US | disclosed |
| EP-1373203-A1 | CYCLOPROPYLINDOLE DERIVATIVES AS SELECTIVE SEROTONIN REUPTAKE INHIBITORS | Bristol-Myers Squibb Company (US) | 2004-01-02 | — | — | EP | disclosed |
| US-20030073849-A1 | Cyclopropylindole derivatives as selective serotonin reuptake inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2003-04-17 | — | — | US | disclosed |
| WO-2002079152-A1 | CYCLOPROPYLINDOLE DERIVATIVES AS SELECTIVE SEROTONIN REUPTAKE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-10-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040143003-A1 | Cyclopropylindole derivatives as selective serotonin reuptake inhibitors | HTR1A, HTR1D, TPH1 | SLC6A4 16/4885ALDH1A1 516/4885DRD2 30/4885 |
| US-20030073849-A1 | Cyclopropylindole derivatives as selective serotonin reuptake inhibitors | HTR5A, HTR1A, HTR2C | SLC6A4 10/4885ALDH1A1 961/4885DRD2 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.